HL7 FHIR Implementation Guide: Common Terminology Criteria (CTC) Adverse Events Release 1 - DRAFT
0.0.1 - DRAFT United States of America flag

HL7 FHIR Implementation Guide: Common Terminology Criteria (CTC) Adverse Events Release 1 - DRAFT, published by HL7 International Clinical Interoperability Council. This guide is not an authorized publication; it is the continuous build for version 0.0.1 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/standardhealth/fsh-ae/ and changes regularly. See the Directory of published versions

Table of Contents

.. 0 Table of Contents
... 1 Home
... 2 Implementation
... 3 Examples Overview
... 4 Persona 1 - Clinical Trials Patient
... 5 Persona 2 - Standard of Care Patient
... 6 Downloads
... 7 Change log
... 8 Artifacts Summary
.... 8.1 CTC Adverse Event
.... 8.2 Adverse Event Expectation
.... 8.3 Adverse Event Participant
.... 8.4 Adverse Event Resolved Date
.... 8.5 Adverse Event Seriousness Outcome
.... 8.6 CTC Adverse Event Grade
.... 8.7 Adverse Event Expectation Value Set
.... 8.8 Adverse Event Participant Function
.... 8.9 Adverse Event Relatedness Value Set
.... 8.10 Adverse Event Seriousness Outcome Value Set
.... 8.11 Adverse Event Seriousness Value Set
.... 8.12 CTCAE Grade Value Set
.... 8.13 CTCAE Terms Value Set
.... 8.14 CTCAE Grade Code System
.... 8.15 ctc-adverse-event-example-1
.... 8.16 ctc-adverse-event-example-2
.... 8.17 ctc-adverse-event-example-3
.... 8.18 patient-example-kaitlyn-b
.... 8.19 PatientPersona2
.... 8.20 PractitionerExample1
.... 8.21 ae-bundle-kaitlyn-compass-trial
.... 8.22 ae-bundle-persona-2
.... 8.23 Alliance COMPASS Trial A011801
.... 8.24 cancer-related-medication-request-doxorubicin2-persona-2
.... 8.25 ctc-adverse-event-anemia1-persona-2
.... 8.26 ctc-adverse-event-anemia2-persona-2
.... 8.27 ctc-adverse-event-compass-ex1
.... 8.28 ctc-adverse-event-compass-ex1a
.... 8.29 ctc-adverse-event-compass-ex1b
.... 8.30 ctc-adverse-event-compass-ex2
.... 8.31 ctc-adverse-event-nausea1-persona-2
.... 8.32 ctc-adverse-event-neutropenia1-persona-2
.... 8.33 ctc-adverse-event-neutropenia2-persona-2
.... 8.34 diagnosticreport-cbc-201-1-persona2
.... 8.35 diagnosticreport-cbc-202-1-persona2
.... 8.36 encounter-ae1-evaluation-persona2
.... 8.37 kaitlyn-primary-cancer-condition-ex1
.... 8.38 medadmin-doxorubicin-persona-2
.... 8.39 medication-administration-kadcyla
.... 8.40 medication-administration-tucatinib
.... 8.41 medication-request-example-kadcyla
.... 8.42 medication-request-example-tucatinib
.... 8.43 medrequest-doxorubicin-persona-2
.... 8.44 OrganizationExample1
.... 8.45 practitioner-oncology-nurse-jane
.... 8.46 primary-cancer-condition-persona-2
.... 8.47 r201-1
.... 8.48 r201-10
.... 8.49 r201-11
.... 8.50 r201-12
.... 8.51 r201-13
.... 8.52 r201-14
.... 8.53 r201-15
.... 8.54 r201-16
.... 8.55 r201-17
.... 8.56 r201-2
.... 8.57 r201-3
.... 8.58 r201-4
.... 8.59 r201-5
.... 8.60 r201-6
.... 8.61 r201-7
.... 8.62 r201-8
.... 8.63 r201-9
.... 8.64 r202-1
.... 8.65 r202-10
.... 8.66 r202-11
.... 8.67 r202-12
.... 8.68 r202-13
.... 8.69 r202-14
.... 8.70 r202-15
.... 8.71 r202-16
.... 8.72 r202-17
.... 8.73 r202-2
.... 8.74 r202-3
.... 8.75 r202-4
.... 8.76 r202-5
.... 8.77 r202-6
.... 8.78 r202-7
.... 8.79 r202-8
.... 8.80 r202-9
.... 8.81 Standard of Care Protocol 0U812
.... 8.82 us-core-organization-acme-laboratory
.... 8.83 us-core-organization-physician-services-inc
.... 8.84 us-core-practitioner-nancy-oncology-nurse
.... 8.85 us-core-practitioner-owen-oncologist